[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100165630":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":18,"responsibleParty":35,"collaborators":7,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":39,"sex":45,"minAge":46,"maxAge":7,"enrollmentInfo":47,"targetDuration":7,"studyType":50,"phases":7,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":56,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Closter Pharma","INDUSTRY",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Sandra M Casiano, M.D.","CONTACT","57-3174049763","scasiano@closterpharma.com",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},"Harold Mejia","57-2264757","hmejia@closterpharma.com",[19],{"facility":20,"status":21,"city":22,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Country Club Bogota","RECRUITING","Bogotá","Colombia","CO",{"type":26,"coordinates":27},"Point",[28,29],-74.08175,4.60971,{"lat":29,"lon":28},[32],{"name":33,"role":34,"phone":7,"phoneExt":7,"email":7},"Andres Romero, MD","PRINCIPAL_INVESTIGATOR",{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100165630","real-life-experience-of-the-use-of-isomers-as-alencal-levamlodipine-for-evaluation-of-efficacy-safety-and-tolerability-in-the-management-of-cardiovascular-disease-in-colombian-patients-100165630",false,"NCT01429233","Real Life Experience of the Use of Isomers as ALENCAL (Levamlodipine) for Evaluation of Efficacy, Safety and Tolerability in the Management of Cardiovascular Disease in Colombian Patients","Real Life Experience of the Use of Isomers as ALENCAL(Levoamlodipine) for Evaluation of Efficacy, Safety and Tolerability in the Management of Cardiovascular Disease in Colombian Patients","XPRES","Inclusion Criteria:\n\n* Patients whose primary physician based on their clinical condition and locally approved use will be eligible to participate in this study, and have been prescribe with Levamlodipine.","ALL","18 Years",{"count":48,"type":49},2000,"ESTIMATED","OBSERVATIONAL","This is a Phase 4, observational, open study in patients whom their doctor for clinical practice prescribes levamlodipine. No medication was provided by the sponsor. The planned observation time is 8 weeks. The 8 weeks of observation involves an evaluation of baseline followed by information gathered from the assessment visits at week 4 and week 8, or clinical practice.",[53],"Hypertension",[55,23],"Observational","UNKNOWN","2011-09-06",{"date":59,"type":49},"2011-09-07",{"date":61,"type":7},"2011-08",{"date":63,"type":49},"2012-03",{"name":5,"class":6},1]